Clinical trial · Observational
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
NCT01047358CI-TRIAL-00019401completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This non-interventional study is to monitor use in real practice in Korea including adverse events on Aromasin (Exemestane).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aromasin | Drug | Exemestane | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- ajuvant group
- description
- adjuvant setting after two to three years of tamoxifen
- interventionNames
- Drug: Aromasin
- label
- palliative group
- description
- palliative setting after progression of disease with anti-estrogen therapy
- interventionNames
- Drug: Aromasin
Primary outcomes (1)
- measure
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
- timeFrame
- From the first dose of Aromasin through the end of the study for an average of 5.6 months
- description
- All AEs reported after start of administration of Aromasin were considered as TEAEs and summarized.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \- Postmenopausal women with breast cancer eligible for hormonal therapy. Exclusion Criteria: * Pregnant breast-feeding premenopausal.
References
Publications (0)
Data not yet available
No reference posted for this study.